Tislelizumab Plus Platinum and Etoposide Versus Placebo Plus Platinum and Etoposide as First-Line Treatment for Extensive-Stage SCLC (RATIONALE-312): A Multicenter, Double-Blind, Placebo-Controlled, Randomized, Phase 3 Clinical Trial
Jilin Province Tumor Hospital · Zhejiang Cancer Hospital · +19 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
116
total citations
- FWCI
- 29.98
- Percentile
- 100%
- References
- 35
Citations per year
Authors
18Topics & keywords
Topics
Keywords
- Medicine
- Hazard ratio
- Internal medicine
- Placebo
- Interquartile range
- Etoposide
- Clinical endpoint
- Carboplatin
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.